Synthesis of Zinc Oxide Nanoparticles with Bioflavonoid Rutin: Characterisation, Antioxidant and Antimicrobial Activities and In Vivo Cytotoxic Effects on Nauplii
Overview
Affiliations
This study aims to synthesise zinc oxide nanoparticles with rutin (ZnO-R NPs) using a green synthesis approach and characterise the nanostructures for diverse biomedical applications. In this study, the optical and chemical properties of synthesised ZnO-R NPs were verified through Fourier transform infrared (FTIR) spectroscopy and ultraviolet-visible (UV-Vis) spectroscopy. The FTIR spectroscopy revealed a symmetric bending vibration peak of 460 cm for ZnO-R NPs, whereas UV-Vis spectroscopy showed a distinct absorption band at 395 nm. Moreover, the oval-shaped morphology of ZnO-R NPs was verified through scanning electron microscopy and transmission electron microscopy. The synthesised nanoformulation revealed a wurtzite structure with a crystallite size of 13.22 nm; however, the zeta potential value was recorded as -8.50 ± 0.46 mV for ZnO-R NPs. According to an antioxidant study, ZnO-R NPs demonstrated lower free-radical scavenging activity than pure rutin. The cytotoxicity study was conducted using a human breast cancer cell line (MCF-7). In vitro analysis verified that ZnO-R NPs exhibited significantly higher anticancer and microbial growth inhibition activities than standard ZnO NPs (ZnO Std NPs) and pure rutin. In addition, ZnO-R NPs revealed a significantly lower IC value than the commercial ZnO Std NPs and pure rutin in MCF-7 cells (16.39 ± 6.03 μg/mL, 27 ± 0.91 μg/mL and 350 ± 30.1 μg/mL, respectively) after 48 h. However, synthesised ZnO-R NPs demonstrated no significant toxicity towards nauplii. These results highlight the synthesis of rutin-mediated ZnO NPs and their possible chemotherapeutic potential.
Alvarez-Sandoval J, Guillen Melendez G, Perez-Hernandez R, Elizondo-Luevano J, Castro-Rios R, Kacaniova M Materials (Basel). 2025; 18(3).
PMID: 39942246 PMC: 11818646. DOI: 10.3390/ma18030580.
Alallam B, Abdkadir E, Hayati A, Keong Y, Lim V Drug Deliv Transl Res. 2025; .
PMID: 39800814 DOI: 10.1007/s13346-024-01777-6.
Mutavski Z, Vidovic S, Ambrus R, Savikin K, Baixinho J, Fernandez N Foods. 2024; 13(23).
PMID: 39683000 PMC: 11641306. DOI: 10.3390/foods13233929.
Liga S, Voda R, Lupa L, Paul C, Nemes N, Muntean D Pharmaceutics. 2024; 16(11).
PMID: 39598587 PMC: 11597859. DOI: 10.3390/pharmaceutics16111464.
Mejia-Mendez J, Reza-Zaldivar E, Sanchez-Martinez A, Ceballos-Sanchez O, Navarro-Lopez D, Marcelo Lozano L J Nanobiotechnology. 2024; 22(1):687.
PMID: 39523303 PMC: 11552316. DOI: 10.1186/s12951-024-02957-9.